The evolutionary implications of recombination in HIV remain not fully understood. A plausible effect could be an enhancement of immune escape from cytotoxic T lymphocytes (CTLs). In order to test this hypothesis, we constructed a population dynamic model of immune escape in HIV and examined the viral-immune dynamics with and without recombination. Our model shows that recombination (i) increases the genetic diversity of the viral population, (ii) accelerates the emergence of escape mutations with and without compensatory mutations, and (iii) accelerates the acquisition of immune escape mutations in the early stage of viral infection. We see a particularly strong impact of recombination in systems with broad, non-immunodominant CTL responses. Overall, our study argues for the importance of recombination in HIV in allowing the virus to adapt to changing selective pressures as imposed by the immune system and shows that the effect of recombination depends on the immunodominance pattern of effector T cell responses.
Citation: Mostowy R, Kouyos RD, Fouchet D, Bonhoeffer S (2011) The Role of Recombination for the Coevolutionary Dynamics of HIV and the Immune Response. PLoS ONE 6(2): e16052. https://doi.org/10.1371/journal.pone.0016052
Editor: Jean-Pierre Vartanian, Institut Pasteur, France
Received: September 30, 2010; Accepted: December 7, 2010; Published: February 18, 2011
Copyright: © 2011 Mostowy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Swiss National Foundation grant number 3100A0-116408 (http://www.snf.ch/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Human immunodeficiency virus (HIV) frequently undergoes recombination –. The high recombination rate is the consequence of both a high switching rate of reverse transcriptase between the two viral RNA strands during proviral synthesis – as well as of the large fraction of infected cells that harbour more than one provirus – (see  for review). Thus, when two non-identical virions infect the same cell, RNA from two different viruses can be packaged into a new virion, and upon a subsequent infection, a crossover event between the two RNA strands can result in Êrecombination of the genetic material (see Fig. 1A). The evolutionary implications of recombination have been, to some extent, addressed in the context of the evolution of anti-retroviral resistance in HIV –. However, the effect of recombination in HIV on coevolutionary dynamics between the virus and the immune system has, to the best of our knowledge, not been addressed.
Panel A: Recombination in HIV occurs in virions that contain two non-identical copies of RNA. During reverse transcription, one or more crossover events between the two strands can take place and result in recombination. Panel B: Immune escape of the infecting virus is modelled by assuming that of the epitopes presented on the surface of infected cells are recognised by the CD8+ T cells. The figure shows a situation for and an infected cell , which contains two epitopes recognised by the immune system () and one epitope that escapes the surveillance of the effector T cells (). Panel C: Escape from immune recognition comes at a fitness cost for the virus, and thus we assume that an escape mutation impairs the reproductive capacity of the pathogen (blue bar). A compensatory mutation partially restores the fitness cost (green bar). In the absence of the escape mutation, the compensatory mutation not only decreases the replicative capacity of the virus but also does not confer immune-resistance (yellow bar).
HIV is known to evade the immune control, for example by escaping from the recognition by cytotoxic T lymphocytes (CTLs). These CTLs recognize and kill cells that display fragments of viral peptides on their surface. More specifically, proteins produced by the virus inside an infected cell are processed by the host cell machinery into antigenic peptides, and loaded onto MHC class I molecules. The resulting MHC:peptide complexes are then presented on the surface of the cell such that the host's CTLs, which scan the MHC:peptide complexes, can recognize and destroy the infected cells. Viruses can evade the immune response, and studies of HIV-1 and SIV infections have shown selection of CTL escape variants during both primary and chronic infections –. The escape is mediated by the ability of the virus to alter the presented peptide sequences (see Fig. 1B). The mutated proteins then become invisible to the antigen-presenting machinery (e.g. TAP or proteasome), dissociate from the MHC molecule, or become unrecognisable to the effector T cell receptors , . On the other hand, escape mutations typically come at a cost to the virus by decreasing the viral replicative capacity , , although compensatory mutations which partially restore the fitness can emerge ,  (see also Fig. 1C). Thus, HIV can efficiently escape the selective pressure of the immune system.
The immune escape dynamics in HIV can generate an environment which is beneficial for recombination. When the immune system generates immune responses against frequent virus strains, a strong selective pressure arises which leads to the escape of the virus. The immune system in turn produces novel responses that can recognize the escape variants and lead to further escape. The resulting coevolutionary arms race between the virus and the immune system resembles the so-called Red Queen dynamics between hosts and parasites, where recombination has been shown to play an important role –. In such a scenario, parasites adapt to infect frequent host genotypes, which gives rare host genotypes a selective advantage. Under these conditions recombination can give the host an edge in the arms race with the parasite by rapidly generating resistant genotypes. Thus in terms of the classical Red Queen terminology, HIV plays the role of the “host” and the immune system plays the role of the “parasite”. Given the parallel between host-parasite coevolution and virus/immune-system dynamics, it is plausible that recombination may, under appropriate conditions, help the virus to escape from the immune system.
In this study, we examine the role of recombination for immune escape of HIV by using a population dynamic model of HIV. We find that recombination accelerates the evolution of escape in the virus in the early stage of infection. We also find that the CTL hierarchy is of vital importance to viral/immune coevolution as well as viral recombination. In particular, we find that the immunodominance pattern of the CTL response strongly affects the mean number of escapes in the virus as well as the impact of recombination. Furthermore, we determine which parameters increase or decrease the impact of viral recombination on the immune escape, and discuss in which situations genetic shuffling could contribute to the viral immune escape as well as to adaptation of HIV to the host in general.
General construction of the model
Mathematical models have proved an excellent tool for studying complex viral dynamics in vivo ,  as well as investigating population genetic and dynamic consequences of recombination . Thus, in order to examine the impact of recombination on the viral immune escape we consider a population dynamic model which is an extension of a standard HIV dynamics model –. The model mimics the interaction of HIV with the immune system by taking into account some basic properties of the coevolutionary dynamics between the virus and the immune system. The model can be expressed by the following set of ordinary differential equations:(1)
Three populations of cells are considered: susceptible naive CD4+ T cells (), infected CD4+ T cells (), and effector CD8+ T cells or CTLs (). Naive target cells, , are produced at a constant rate , and die at a rate . They can become infected by any of distinct viral strains in the population. A naive T cell infected by a virus strain becomes an infected cell of type . The virus is assumed to be in quasi-steady state , which implies that free virus is, to a good approximation, proportional to the infected cells at all times. The transmission rate of an infected CD4+ cell of type is then defined as , where denotes the transmission rate by cells infected with a wild-type strain and denotes the relative reproductive fitness of the virus strain (which implies that ).
An infected cell displays distinct types of MHC:peptide complexes, all of which are recognized at the beginning of infection by effector cells (CTL of type recognizes an epitope ). Mutations at these epitopes can lead to escape from recognition by CTLs and here we focus solely on those mutations that result in a complete lack of recognition by the immune system. Whether the clone recognizes the viral strain is defined in a binary interaction matrix , where 1 denotes recognition and 0 denotes escape (see Fig. 1B). We assume that each viral epitope consists of two loci: an escape locus and a compensatory locus. A single mutation in either locus leads to an impairment of the replicative capacity respective to the wild-type (each fitness value is randomly drawn from a uniform distribution between and 1), while a double mutation partially restores it (uniformly drawn from the higher fitness of the two loci and 1; see Fig. 1C). The fitness of each strain , , is then the product of individual epitope fitness values .
All infected cells die at a rate due to reasons other than immune killing (e.g. cytopathicity), and we assume that . In addition, they are killed by the immune response at a rate per day, where is the maximal death rate of infected cells due to CTL killing and is the number of CTLs in the steady state in the absence of escape (see Table 1). Furthermore, the strength of killing depends on how well the viral strain is recognized by the immune system, and hence is proportional to the number of CTLs specific for the particular strain , namely . Likewise, the activation and production of the effector sub-population is proportional to the viral sub-population recognized by this clone. The effector cells are produced at a constant rate , are activated to proliferate at a maximal rate , and die at a rate .
The rates of new infections and CTL production are assumed to obey Michaelis-Menten dynamics, which generates a saturation effect in these terms similar to the Michaelis-Menten enzyme-substrate kinetics , , . By dividing the standard mass-action term by the density of the cells that undergo such kinetics, one generates more realistic and less oscillatory population dynamics of virus/immune-system interactions. The terms describing target cell depletion and the increase of infected cells saturate as a function of the total of naive and infected CD4+ cells, reflecting the T cell density-dependence of the transmission rate . Likewise, the proliferation via activation of the CTLs saturates as a function of infected cells and effector cells reflecting a non-trivial CTL kinetics in vivo, including competition for antigen and saturation in killing , , . The constant is a dissociation parameter, which is an inverse of the measure of sensitivity (avidity; see below) of the effector T cell clone : low corresponds to a sensitive clone, and high corresponds to an insensitive clone. By varying the distribution of the parameter , the immunodominance of an effector response is altered. The overview of parameters together with the assumed values is given in Table 1.
Mutation and recombination
Mutation and recombination are implemented as stochastic events and are executed at discrete time steps during the simulation. When new mutants and recombinants are generated, the ancestral viruses are removed from the population of infected cells, new strains are added, and the set of equations (2) is restructured accordingly. Importantly, both mutation and recombination do not alter the number of infected cells but only the genetic composition of the provirus population.
In order to perform mutation, we approximate the number of CD4+ cells infected with a single virus of type between the time and as
In order to perform recombination, we assume at every time-point that (i) a fraction of all infected cells is doubly infected, (ii) amongst these doubly infected cells, the cells infected with two different strains and occur at a frequency , which implies that the infection of a target cell by one virus strain happens independently from infection of the same target cell by another virus strain, (iii) a cell doubly infected with virus strains and produces a new infection between the time and with the probability
(3)(iv) in the course of such infection event, strains and are enclosed in the same viral capsule with the probability of 50%, and that (v) the average number of crossover events is equal to and crossover-sites are randomly distributed across the viral genome. Likewise, the newly recombined strains substitute the old strains in the population of infected cells.
We distinguish between two types of escape, E and EC. The escape E is the escape which only carries a mutation at the escape locus and regardless of the type of allele at the compensatory locus; the escape EC is the escape which carries a mutation at both escape locus and the compensatory locus (see Fig. 1C). Unless mentioned which type of escape mutation is analyzed, we refer to the E escape type.
Time of escape.
The average time of escape of a mutant with escape mutations is measured by calculating the total abundance of CD4+ cells infected with viruses with escape mutations and capturing the time when the number of these cells exceeds .
Mean number of escapes.
The mean number of escape variants in the population at a given time is calculated by the mean Hamming distance of the escape types from the wild type. For example, in order to calculate the mean number of E escape variants, we calculate the abundance of all strains with the number of E escapes equal to zero, one, two, etc., then multiply each by its Hamming distance from the wild type, and finally weight by the total virus load.
Each CTL clonal sub-population has its assigned sensitivity (avidity) value , where is the Michaelis-Menten constant assigned to each clone. Thus, the least sensitive population has mean avidity of 1. For each run (unless mentioned otherwise), we randomly choose the values between and .
The diversity of the CTL population is a measure of their distribution. At each time point in one simulation run we calculated the diversity of the CTL response by the use of the Shannon diversity index where is a frequency of each CTL clone and is the number of CTL clones. The mean diversity was calculated by first averaging over all simulations runs and then over time.
The aim of this study was to examine the impact of recombination on the immune escape of HIV. To that end, we considered a deterministic, population dynamic model of HIV infection with a stochastic implementation of mutation and recombination –, and examined the viral-immune dynamics with and without recombination (see Methods). Using the model we quantified the impact of recombination on a number of important characteristics of the viral population (viral load, emergence of escape, diversity, etc.) as well as a number of important characteristics of the immune system (strength, distribution of CTL clones, etc.).
Recombination accelerates the acquisition of escape mutations
A key question is whether recombination can accelerate the emergence of escape mutations in HIV, and if so, whether this is beneficial for the virus. Fig. 2 shows two representative simulation runs of the immune escape dynamics with and without recombination. The figure shows the frequencies of escape mutations at different epitope loci with three chosen escape frequencies shown in colour. Fig. 2A shows an example of dynamics where the impact of recombination is high. Fig. 2B shows an example of dynamics where the impact of recombination is low. This illustrates that recombination can, but does not generally accelerate the emergence and the fixation of immune escape. Furthermore, the distinct escape dynamics which can be seen in both panels suggest that the characteristics of the immune response play an important role in the scale of the recombination impact, as will become evident in the next section. (Even though the virus recombines with the same strength, the properties of not only the virus but also the immune system lead to a much weaker effect of recombination.)
Simulation runs without recombination are shown with solid lines, and with recombination with dashed lines. Plotted are frequencies of escapes at all loci as a function of time, and in each case three chosen loci are printed in colour. Panel A shows an example simulation run for a parameter setting in which the impact of recombination is strong. Panel B shows an example simulation run for a parameter setting in which the impact of recombination is weak. Recombination mostly, but not always, accelerates the emergence and fixation of immune escapes. Parameters used in panel A: , , . Parameters used in panel B: , ; the remaining parameters are the same and are defined in Table 1.
In order to assess a general impact of recombination on the evolution of escape in HIV, we measured the mean time of appearance of escape mutations during infection. In particular, we measured an average speed of accumulation of successive mutations from the time point of infection, i.e. the average time of appearance of a single mutant, the average time of appearance of a double mutant, etc. The results are presented in Fig. 3 where panel A shows the average times of appearance of successive E escape mutants and panel B shows the average times of appearance of successive EC escape mutants (see Methods and Fig. 1C for an explanation of E and EC escape mutants).
In both panels the time of emergence of mutants with a given number of escape mutations is shown. Orange and blue bars correspond to runs with and without recombination, respectively. A shows the time of appearance of E escapes (escapes at the escape locus). Panel B shows the time of appearance of EC escapes (escapes at the escape and compensatory locus). The simulations show that recombination accelerates the emergence of escape mutations. Parameters used: , ; the others are defined in Table 1. The plot shows an average of 10000 simulation runs.
The figure shows that in runs with recombination successive escape variants appear faster than in the runs without recombination, and that the accumulating effect of recombination increases with the number of escape mutations. The impact of recombination is even stronger for EC than for E escape types. Since EC escapes need two point mutations, the results suggest that genetic shuffling not only helps bringing together escape mutations from different epitopes but also bringing together escape and compensatory mutations at the same epitope (see Discussion). Thus, our model shows that recombination accelerates the emergence of escape variants by clustering together various escape mutations in the virus.
On the other hand, the acceleration of the emergence of escape mutations is likely to have other consequences on the virus dynamics, and thus we next examined which of the determinants of the viral population are significantly affected by genetic shuffling. We found that recombination has a considerable impact on viral diversity as well as the average number of escape mutations in the population. The results are shown in Fig. 4 where the average over many stochastic simulation runs is considered. Fig. 4A shows the viral genetic diversity as a function of time since the beginning of infection. One can see that due to the faster appearance of escape variants, a higher level of genetic diversity is achieved in virus populations with recombination. Fig. 4B shows the mean number of E escapes in the viral population as a function of time (see Methods). The runs with recombination resulted in an increased level of escape on the population scale early in the infection, however after 2–3 years the same runs () showed only a marginally higher number of escapes than the runs without recombination (). The initial increase in the number of escapes occurred because of a high selective pressure to escape the CTL responses, resulting in a subsequent decrease of the stimulation of T cells and hence of the selective pressure. At the same time, an increase in the mean number of escapes decreased the fitness of the virus population, making it susceptible to the invasion by strains with the wild-type allele (results not shown). As a result, the escape epitopes became selected against during the chronic stage of infection.
Orange and blue bars correspond to runs with and without recombination, respectively. Panel A shows the viral diversity as a number of strains in the population (results for other measures of diversity were qualitatively similar). It can be seen that recombination has a significant impact on diversity regardless of the stage of infection. Panel B shows the mean number of escapes measured by the mean HD at the escape loci. The panel shows that recombination accelerates the evolution of immune escape in the virus in the early phase of infection because it accelerates the acquisition of the escape mutations when they are beneficial. Note that the strain with mutations at all loci (HD = 30) has arisen only in the runs with recombination (one blue bar missing in panel B). The parameters are identical as in Fig. 3 and the plot also shows an average of 10000 simulation runs.
In line with this interpretation, we observed little or no reversion to the wild-type in simulations where the cost of escape was low or absent (results not shown). The higher mean number of escapes with suggests that the process of selecting escape variants in the primary phase of infection was accelerated by the mechanism of recombination. Interestingly, we observed that recombination had no significant effect on the viral load unless the process of escape led to the appearance of an escape mutant with a substantially decreased kill rate and a relatively high replicative capacity (results not shown; see Discussion).
CTL dynamics and the impact of recombination
Several measures of the T cell response are used extensively in immunological literature (e.g. immunodominance, breadth, strength). However, using them to characterize the CTL dynamics during a viral infection has the disadvantage that these measures not only result from the properties of the immune cells but are are strongly affected by the interactions of the immune response with the virus and the stochastic effects. In order to characterize the response itself, one could measure the avidity distribution of the T cell population for a given antigen, but such quantification in experimental assays remains not feasible. A mathematical model, on the other hand, has the advantage that the sensitivity of each CD8+ T cell clone to the wild-type virus is defined before the simulation run (by the avidity value ; see Methods). Therefore, in this study we propose to quantify the CTL response by the mean avidity and the variance of avidity in each run. In this way, (a) two independent variables are used to quantify the immune response, while typical measures used in the literature can be read off the plot, and (b) a correspondence between the measures of the T cell population and the observed immune dynamics are investigated.
The results are displayed in Fig. 5 where panel A shows the diversity of the CTL response as a function of mean and variance of the T cell avidity (see Methods) averaged over many simulations ( assumed but results for are qualitatively the same). As expected, the diversity of the CTL response decreases (responses become more even) as the variance of avidity decreases (low diversity for low avidity occurs because all clones are equally weak). However, increasing the mean avidity at a constant variance (with the exception of the zero variance and the very weak response) increases the evenness and hence the breadth of the response. Thus we see that the relation between the avidity and the breadth of the response can be non-trivial and counter-intuitive.
Figures are plotted as a function of mean avidity and variance of avidity of the CTL response. Panel A shows the mean diversity of the CTL population which decreases with increasing mean (except for an initial increase in avidity) and decreasing variance in avidity. Panel B shows the mean number of escapes during infection without recombination after 1 yr. of infection, which has an optimum for a given mean avidity of response and correlates well with the diversity of the CTL response in panel A. Panel C shows the factor of increase in the number of escapes after one year (cf. panel B) due to recombination, which is the strongest for broad and even responses. Panels D and E show the time of appearance (days) of the full escape variant without and with recombination, respectively. The hatched areas show runs in which the full escape mutant did not appear within the time of 1000 days. The impact of recombination on the time of emergence of the full escape mutant, shown in panel F, corresponds well to the impact of recombination on the number of escape mutations after one year, shown in panel C. The mean and variance of log avidities ( and , respectively) plotted in all panels are defined in each simulation, and the distribution of avidity values is drawn from a uniform distribution in each simulation run between and . The parameters used: , , . All other parameters are given in Table 1. Each point in the plot shows an average of 5000 simulation runs.
Fig. 5B shows the mean number of escapes at the escape loci after one year from infection, as a function of the mean and the variance of avidity. Fig. 5C shows the factor of increase in the measure in panel B due to recombination. One can see that as the potency (mean avidity) of the immune response increases, the efficiency of escape reaches an optimum, namely an initial increase in the impact of recombination is followed by a decrease. The initial increase occurs because with a higher avidity the strength of the immune system increases and so does the selective pressure. However, as explained above, by increasing the mean avidity the hierarchy of the immune response changes yielding a broader CTL response. Such immune response effectively targets the virus at many loci, disabling the evasion of the immune system (escape becomes too costly). However, at the same time that the immune response broadens, the impact of recombination becomes stronger. This is particularly evident for potent and non-immunodominant CTL responses, i.e. for runs with high mean and small variance in avidity. We see qualitatively the same pattern when measuring the acceleration of the appearance of the full escape mutant (Fig. 5D–F).
Why is the impact of recombination stronger for broader (non-immunodominant) responses? The reason is that when all effector responses are similarly strong, the expected time of escape at any epitope will be comparable, meaning that all epitopes will escape on average at a similar time because they will all become advantageous at a similar time. A multiple number of escape variants increasing in frequency will in turn allow for almost any combination of those mutations to be advantageous too, possibly outgrowing variants with a smaller number of escape epitopes. This creates an environment in which genetic shuffling will have a significant effect. By contrast, immunodominant responses will favour different escape variants at different times, which will decrease the diversity in the viral population, and hence the variance which recombination can act on. This is why we see a stronger impact of recombination on the number of escapes in models with little or no immunodominance.
We also examined the impact of recombination for a decreased cost of escape, and, in accordance with the intuition, we observed an increased effect of recombination on the emergence of escapes (results not shown). With decreasing cost of escape, the impact of recombination on the emergence of escape variants increased markedly. This is because fitter escape variants competed more efficiently with the wild-type variants which in turn, by increasing viral diversity, enhanced the impact of recombination. Finally, as we observed that a decreased level of immunodominance is generally associated with an increased breadth of the response and also with an increased number of CD8+ cells, we conclude that broader and stronger (higher activation and killing) immune responses are likely to increase the impact of viral recombination on the escape dynamics.
In this study we show that recombination in HIV accelerates the initial phase of viral coevolution with the immune system. We demonstrate that random shuffling of the genetic material (a) accelerates the emergence of escape mutations (both with and without compensatory mutations), (b) increases viral diversity during infection (in line with the experimental observations; see ), (c) accelerates the acquisition of escape mutations in the early stage of infection. Furthermore, our model exhibits a negative correlation between the impact of recombination and the efficiency of escaping the immune system. In particular, we observe that the impact of recombination is strongest in broad, non-immunodominant systems. Although our analysis focuses on the escape from cytotoxic T-lymphocytes, similar effect might occur with escape from other virus-specific responses including antibodies.
Generally, we see a higher impact of recombination with than without compensatory mutations, suggesting an acceleration in the adaptation of the virus due to recombination in spite of positive epistasis (a double mutant has higher fitness than a single mutant). This may seem paradoxical as under positive epistasis, recombination may be expected to decelerate adaptation . We see three potential explanations for this paradox: (i) stochastic effects in this model may override the effects of possible epistasis ; (ii) the epistasis experienced by the virus is also influenced by the CTL dynamics, and these could therefore outweigh the positive epistasis of compensatory mutations with respect to reproductive fitness; and (iii) more generally the model here is substantially more complex than the population genetic models that have been used to determine the mentioned effects of epistasis on recombination, such that it is difficult to translate their observation to the situation considered here.
Depending on the total fitness cost of escape, and thus also on the number of escape loci, a mutant can arise that escapes at all loci. Because such full escape is no longer controlled by the immune response, the appearance of this mutant is accompanied by a substantial increase in viral load. The time of appearance of the full escape mutant depends strongly on the recombination rate. However, whether such total escape ever occurs in late stage patients is currently unclear.
Generally, we find that viral recombination increases the set-point viral load. Given the moderate magnitude of this increase (typically 5–10%, data not shown) and the large variance seen between clinical measurements of the virus load, it is not an effect that could easily be detected in clinical data even if there were considerable variation in recombination rates between different viral isolates. The fact that in our model recombination has only a weak effect on virus load, however, is compatible with strong selective pressures on escape mutants, as observed experimentally , –, because large changes in viral fitness in vivo do not necessarily induce substantial changes in virus load , .
As common strains are likely to be targeted more strongly by the immune response, a negative frequency dependent selection may ensue, leading to potentially cyclical frequency dynamics between the virus and the immune system. This behaviour shows a resemblance with the so-called Red Queen dynamics in evolutionary biology, where fluctuating selection in host-parasite systems leads to allele frequency cycles and the maintenance of genetic variants over long periods of time. One of the leading hypothesis for the evolution of recombination (Red Queen Hypothesis) states that such circumstances can explain the evolutionary maintenance of genetic shuffling – (see  for a review). Here, we have focused on examining the consequences rather than the evolution of recombination rate. Nevertheless, the fact that viral recombination accelerates the acquisition of beneficial mutations in the virus indicates that recombination, like in the Red Queen scenario, could be advantageous for the virus. However, our model differs in a number of ways from the typical Red Queen models (multiple loci, absence of persistent allele fluctuations, interaction models, etc.), and whether the observed benefit of recombination stems from the similar effects as in the Red Queen Hypothesis is a topic that warrants further investigation.
Although the primary aim of this study has been the impact of recombination on the coevolution of HIV with the immune system, the results presented here might shed light on the evolutionary history of recombination in HIV (or other retroviruses like SIV). On the one hand, we have found that recombination can have a strong impact on the speed of acquisition of escape mutations, and thus arguably, on the adaptation of the virus to the new hosts. This suggests that the within-host selection acting on the virus might select for non-zero recombination rates. On the other hand, the total viral load has been correlated with the transmission probability of HIV, and since we have seen that recombination moderately increases the total virus load, the between-host selection acting on the viral recombination is likely to be weak or zero. This also emphasizes the importance of the within-host stage of evolution of HIV. However, what evolutionary forces act on recombination and how, as well as whether HIV had enough time to evolve its recombination rate, remains a matter of discussion.
HIV and the immune system remain one of the best qualitatively and quantitatively characterized coevolutionary systems. However, a better insight into the coevolutionary dynamics underlying the interaction of the virus with the immune system, as well as into the population dynamical consequences of recombination, requires an improved understanding of the parameter space defining these interactions. First, the recently underlined importance of macrophages in the development of HIV infection  as well as of an increased recombination rate in those cells  suggests that the inclusion of macrophages in a model of recombination might qualitatively affect the outcome of this study. Second, we have seen a positive correlation between the number of crossover events in HIV and the mean number of escape mutants in the late stage of infection (results not shown). Therefore, a better understanding of the relation between viral fitness in vivo and the number of escape mutations in the chronic phase of the infection might yield further insight into understanding the optimal recombination rate in HIV. Third, our results show that of particular importance is the estimation of the fitness of escape mutants in the context of the immune system (in vivo). The first component of this fitness is the cost that these mutations induce in the absence of the immune response, which could be measured by quantifying their effect on the replicative capacity of HIV in vitro. The other component of the fitness in vivo reflects the interaction of the virus and the immune response. This is encapsulated by the parameter avidity, which describes both the activation of the immune response by the virus as well as its subsequent recognition and the killing by the immune system. Obtaining more quantitative data on the specificity and diversity of the T cell repertoire recognizing the virus would allow better understanding of the effect of recombination on the population dynamics of the virus, and more generally would enable more quantitative approach to the causes underlying immunodominance.
We thank Viktor Müller and Roland R. Regoes for careful reading of the manuscript. We also acknowledge Frederik Graw for helpful discussions concerning the CTL kinetics.
Conceived and designed the experiments: RM RDK SB. Performed the experiments: RM. Analyzed the data: RM RDK DF SB. Contributed reagents/materials/analysis tools: SB. Wrote the paper: RM.
- 1. Onafuwa-Nuga A, Telesnitsky A (2009) The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 73: 451–480.A. Onafuwa-NugaA. Telesnitsky2009The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.Microbiol Mol Biol Rev73451480
- 2. Robertson DL, Sharp PM, McCutchan FE, Hahn BH (1995) Recombination in HIV-1. Nature 374: 124.DL RobertsonPM SharpFE McCutchanBH Hahn1995Recombination in HIV-1.Nature374124
- 3. Wooley DP, Smith RA, Czajak S, Desrosiers RC (1997) Direct demonstration of retroviral recombination in a rhesus monkey. J Virol 71: 9650.DP WooleyRA SmithS. CzajakRC Desrosiers1997Direct demonstration of retroviral recombination in a rhesus monkey.J Virol719650
- 4. An W, Telesnitsky A (2002) HIV-1 genetic recombination: experimental approaches and observations. AIDS Rev 4: 195–212.W. AnA. Telesnitsky2002HIV-1 genetic recombination: experimental approaches and observations.AIDS Rev4195212
- 5. Chen J, Powell D, Hu WS (2006) High frequency of genetic recombination is a common feature of primate lentivirus replication. J Virol 80: 9651–9658.J. ChenD. PowellWS Hu2006High frequency of genetic recombination is a common feature of primate lentivirus replication.J Virol8096519658
- 6. Kuwata T, Miyazaki Y, Igarashi T, Takehisa J, Hayami M (1997) The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains. J Virol 71: 7088–7091.T. KuwataY. MiyazakiT. IgarashiJ. TakehisaM. Hayami1997The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains.J Virol7170887091
- 7. Rhodes T, Wargo H, Hu WS (2003) High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 77: 11193–11200.T. RhodesH. WargoWS Hu2003High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication.J Virol771119311200
- 8. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S (2000) Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Nat Acad Sci 97: 14566–14571.S. GrattonR. CheynierMJ DumaurierE. OksenhendlerS. Wain-Hobson2000Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers.Proc Nat Acad Sci971456614571
- 9. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, et al. (2002) Recombination: multiply infected spleen cells in HIV patients. Nature 418: 144.A. JungR. MaierJP VartanianG. BocharovV. Jung2002Recombination: multiply infected spleen cells in HIV patients.Nature418144
- 10. Quiñones-Mateu ME, Arts EJ (1999) Recombination in HIV-1: update and implications. Aids Rev 1: 89–100.ME Quiñones-MateuEJ Arts1999Recombination in HIV-1: update and implications.Aids Rev189100
- 11. Althaus CL, Bonhoeffer S (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572.CL AlthausS. Bonhoeffer2005Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1.J Virol7913572
- 12. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004) Evidence for positive epistasis in HIV-1. Science 306: 1547.S. BonhoefferC. ChappeyNT ParkinJM WhitcombCJ Petropoulos2004Evidence for positive epistasis in HIV-1.Science3061547
- 13. Fraser C (2005) HIV recombination: what is the impact on antiretroviral therapy? J R Soc Interface 2: 489.C. Fraser2005HIV recombination: what is the impact on antiretroviral therapy?J R Soc Interface2489
- 14. Kouyos RD, Fouchet D, Bonhoeffer S (2009) Recombination and drug resistance in HIV: Population dynamics and stochasticity. Epidemics 1: 58–69.RD KouyosD. FouchetS. Bonhoeffer2009Recombination and drug resistance in HIV: Population dynamics and stochasticity.Epidemics15869
- 15. Moutouh L, Corbeil J, Richman DD (1996) Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Nat Acad Sci 93: 6106–6111.L. MoutouhJ. CorbeilDD Richman1996Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.Proc Nat Acad Sci9361066111
- 16. Vijay NNV, Ajmani R, Perelson AS, Dixit NM (2008) Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J Gen Virol 89: 1467.NNV VijayR. AjmaniAS PerelsonNM Dixit2008Recombination increases human immunodeficiency virus fitness, but not necessarily diversity.J Gen Virol891467
- 17. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205–211.P. BorrowH. LewickiX. WeiMS HorwitzN. Peffer1997Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.Nat Med3205211
- 18. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, et al. (2004) Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 199: 905–915.R. DraenertS. Le GallKJ PfafferottAJ LeslieP. Chetty2004Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.J Exp Med199905915
- 19. Jones N, Wei X, Flower D, Wong M, Michor F, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200: 1243.N. JonesX. WeiD. FlowerM. WongF. Michor2004Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.J Exp Med2001243
- 20. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453–459.RE PhillipsS. Rowland-JonesDF NixonFM GotchJP Edwards1991Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.Nature354453459
- 21. Goulder PJR, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4: 630–640.PJR GoulderDI Watkins2004HIV and SIV CTL escape: implications for vaccine design.Nat Rev Immunol4630640
- 22. Lopez M, Soriano V, Benito JM (2007) Escape Mutations in HIV Infection and its Impact on CD8 T Cell Responses. Curr Mol Med 7: 446–458.M. LopezV. SorianoJM Benito2007Escape Mutations in HIV Infection and its Impact on CD8 T Cell Responses.Curr Mol Med7446458
- 23. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, et al. (2005) Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79: 5721–5731.CS FernandezI. StratovR. De RoseK. WalshCJ Dale2005Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost.J Virol7957215731
- 24. Liu Y, McNevin J, Zhao H, Tebit DM, Troyer RM, et al. (2007) Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 81: 12179–12188.Y. LiuJ. McNevinH. ZhaoDM TebitRM Troyer2007Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.J Virol811217912188
- 25. Friedrich TC, Frye CA, Yant LJ, O'Connor DH, Kriewaldt NA, et al. (2004) Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol 78: 2581.TC FriedrichCA FryeLJ YantDH O'ConnorNA Kriewaldt2004Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response.J Virol782581
- 26. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27–restricted cytotoxic T lymphocyte responses. J Exp Med 193: 375–386.AD KelleherC. LongEC HolmesRL AllenJ. Wilson2001Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27–restricted cytotoxic T lymphocyte responses.J Exp Med193375386
- 27. Hamilton WD, Axelrod R, Tanese R (1990) Sexual Reproduction as an Adaptation to Resist Parasites (A Review). Proc Nat Acad Sci 87: 3566–3573.WD HamiltonR. AxelrodR. Tanese1990Sexual Reproduction as an Adaptation to Resist Parasites (A Review).Proc Nat Acad Sci8735663573
- 28. Otto SP, Nuismer SL (2004) Species Interactions and the Evolution of Sex. Science 304: 1018–1020.SP OttoSL Nuismer2004Species Interactions and the Evolution of Sex.Science30410181020
- 29. Salathé M, Kouyos RD, Bonhoeffer S (2008) The state of affairs in the kingdom of the Red Queen. Trends Ecol Evol 23: 439–445.M. SalathéRD KouyosS. Bonhoeffer2008The state of affairs in the kingdom of the Red Queen.Trends Ecol Evol23439445
- 30. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126.DD HoAU NeumannAS PerelsonW. ChenJM Leonard1995Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature373123126
- 31. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117–122.X. WeiSK GhoshME TaylorVA JohnsonEA Emini1995Viral dynamics in human immunodeficiency virus type 1 infection.Nature373117122
- 32. Otto SP, Lenormand T (2002) Resolving the paradox of sex and recombination. Nat Rev Gen 3: 252–261.SP OttoT. Lenormand2002Resolving the paradox of sex and recombination.Nat Rev Gen3252261
- 33. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, et al. (1995) Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections. Nature 375: 606–611.MA NowakRM MayRE PhillipsS. Rowland-JonesDG Lalloo1995Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections.Nature375606611
- 34. De Boer RJ (2007) Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus. J Virol 81: 2838–2848.RJ De Boer2007Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.J Virol8128382848
- 35. Althaus CL, De Boer RJ (2008) Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol 4: e1000103.CL AlthausRJ De Boer2008Dynamics of immune escape during HIV/SIV infection.PLoS Comput Biol4e1000103
- 36. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782–1785.B. RamratnamS. BonhoefferJ. BinleyA. HurleyL. Zhang1999Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.Lancet35417821785
- 37. Müller V, Marée AF, De Boer RJ (2001) Small variations in multiple parameters account for wide variations in HIV–1 set–points: a novel modelling approach. Proc Roy Soc B 268: 235–242.V. MüllerAF MaréeRJ De Boer2001Small variations in multiple parameters account for wide variations in HIV–1 set–points: a novel modelling approach.Proc Roy Soc B268235242
- 38. Segel LA (1988) On the validity of the steady state assumption of enzyme kinetics. Bull Math Biol 50: 579–593.LA Segel1988On the validity of the steady state assumption of enzyme kinetics.Bull Math Biol50579593
- 39. Graw F, Regoes RR (2009) Investigating CTL Mediated Killing with a 3D Cellular Automaton. PLoS Comput Biol 5: e1000466.F. GrawRR Regoes2009Investigating CTL Mediated Killing with a 3D Cellular Automaton.PLoS Comput Biol5e1000466
- 40. Yates A, Graw F, Barber DL, Ahmed R, Regoes RR, et al. (2007) Revisiting estimates of CTL killing rates in vivo. PLoS One 2: e1301.A. YatesF. GrawDL BarberR. AhmedRR Regoes2007Revisiting estimates of CTL killing rates in vivo.PLoS One2e1301
- 41. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ (2006) Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80: 2472–2482.C. CharpentierT. NoraO. TenaillonF. ClavelAJ Hance2006Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.J Virol8024722482
- 42. Bretscher MT, Althaus CL, Müller V, Bonhoeffer S (2004) Recombination in HIV and the evolution of drug resistance: for better or for worse? Bioessays 26: 180–188.MT BretscherCL AlthausV. MüllerS. Bonhoeffer2004Recombination in HIV and the evolution of drug resistance: for better or for worse?Bioessays26180188
- 43. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, et al. (2004) Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 78: 7069–7078.TM AllenM. AltfeldXG YuKM O'SullivanM. Lichterfeld2004Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.J Virol7870697078
- 44. Asquith B, Edwards CT, Lipsitch M, McLean AR (2006) Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biology 4: e90.B. AsquithCT EdwardsM. LipsitchAR McLean2006Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo.PLoS Biology4e90
- 45. Asquith B, McLean AR (2007) In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques. Proc Nat Acad Sci 104: 6365–6370.B. AsquithAR McLean2007In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques.Proc Nat Acad Sci10463656370
- 46. Mandl JN, Regoes RR, Garber DA, Feinberg MB (2007) Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape. J Virol 81: 11982–11991.JN MandlRR RegoesDA GarberMB Feinberg2007Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape.J Virol811198211991
- 47. O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, et al. (2004) A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 78: 14012–14022.DH O'ConnorAB McDermottKC KrebsEJ DoddsJE Miller2004A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation.J Virol781401214022
- 48. Bonhoeffer S, Coffin JM, Nowak MA (1997) Human immunodeficiency virus drug therapy and virus load. J Virol 71: 3275–3278.S. BonhoefferJM CoffinMA Nowak1997Human immunodeficiency virus drug therapy and virus load.J Virol7132753278
- 49. Bonhoeffer S, Funk GA, Günthard HF, Fischer M, Müller V (2003) Glancing behind virus load variation in HIV-1 infection. TRENDS Microbiol 11: 499–504.S. BonhoefferGA FunkHF GünthardM. FischerV. Müller2003Glancing behind virus load variation in HIV-1 infection.TRENDS Microbiol11499504
- 50. Bell G (1982) The Masterpiece of Nature: The Evolution and Genetics of Sexuality. Kluwer Academic Publishers. G. Bell1982The Masterpiece of Nature: The Evolution and Genetics of Sexuality.Kluwer Academic Publishers
- 51. Hamilton WD (1976) Gamblers since life began: barnacles, aphids, elms. Quart Rev Biol 51: 407–412.WD Hamilton1976Gamblers since life began: barnacles, aphids, elms.Quart Rev Biol51407412
- 52. Jaenike J (1978) An hypothesis to account for the maintenance of sex within populations. Evol Theory 3: 191–194.J. Jaenike1978An hypothesis to account for the maintenance of sex within populations.Evol Theory3191194
- 53. Benaroch P, Billard E, Gaudin R, Schindler M, Jouve M (2010) HIV-1 assembly in macrophages. Retrovirology 7: P. BenarochE. BillardR. GaudinM. SchindlerM. Jouve2010HIV-1 assembly in macrophages.Retrovirology7
- 54. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Nat Acad Sci 101: 4204–4209.DN LevyGM AldrovandiO. KutschGM Shaw2004Dynamics of HIV-1 recombination in its natural target cells.Proc Nat Acad Sci10142044209
- 55. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, et al. (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 5: 83–89.M. HellersteinMB HanleyD. CesarS. SilerC. Papageorgopoulos1999Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans.Nat Med58389
- 56. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD (1998) Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279: 1223–1227.H. MohriS. BonhoefferS. MonardAS PerelsonDD Ho1998Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.Science27912231227
- 57. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285–301.MA StaffordL. CoreyY. CaoES DaarDD Ho2000Modeling plasma virus concentration during primary HIV infection.J Theor Biol203285301
- 58. Petravic J, Ribeiro RM, Casimiro DR, Mattapallil JJ, Roederer M, et al. (2008) Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. J Virol 82: 11589–11598.J. PetravicRM RibeiroDR CasimiroJJ MattapallilM. Roederer2008Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections.J Virol821158911598
- 59. Asquith B, Mosley AJ, Barfield A, Marshall SEF, Heaps A, et al. (2005) A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol 86: 1515–1523.B. AsquithAJ MosleyA. BarfieldSEF MarshallA. Heaps2005A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load.J Gen Virol8615151523
- 60. Regoes RR, Barber DL, Ahmed R, Antia R (2007) Estimation of the rate of killing by cytotoxic T lymphocytes in vivo. Proc Nat Acad Sci 104: 1599–1603.RR RegoesDL BarberR. AhmedR. Antia2007Estimation of the rate of killing by cytotoxic T lymphocytes in vivo.Proc Nat Acad Sci10415991603
- 61. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037–5038.M. MarkowitzM. LouieA. HurleyE. SunM. Di Mascio2003A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.J Virol7750375038
- 62. Davenport MP, Ribeiro RM, Perelson AS (2004) Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol 78: 10096–10103.MP DavenportRM RibeiroAS Perelson2004Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.J Virol781009610103
- 63. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, et al. (1999) Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy. J Virol 73: 797–800.GS OggX. JinS. BonhoefferP. MossMA Nowak1999Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy.J Virol73797800
- 64. Casazza JP, Betts MR, Picker LJ, Koup RA (2001) Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 75: 6508–6516.JP CasazzaMR BettsLJ PickerRA Koup2001Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.J Virol7565086516
- 65. Butz EA, Bevan MJ (1998) Massive expansion of antigen-specific CD8 T cells during an acute virus infection. Immunity 8: 167–175.EA ButzMJ Bevan1998Massive expansion of antigen-specific CD8 T cells during an acute virus infection.Immunity8167175
- 66. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081–2092.MM AddoXG YuA. RathodD. CohenRL Eldridge2003Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.J Virol7720812092
- 67. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, et al. (2009) Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 83: 1845–1855.YE WangB. LiJM CarlsonH. StreeckAD Gladden2009Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1.J Virol8318451855
- 68. Parera M, Fernàndez G, Clotet B, Martnez MA (2007) HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol 24: 382.M. PareraG. FernàndezB. ClotetMA Martnez2007HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.Mol Biol Evol24382
- 69. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087–5094.LM ManskyHM Temin1995Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.J Virol6950875094
- 70. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, et al. (2000) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74: 1234–1240.AE JetztH. YuGJ KlarmannY. RonBD Preston2000High rate of recombination throughout the human immunodeficiency virus type 1 genome.J Virol7412341240
- 71. Josefsson L, Palmer S, Casazza J, Ambrozak D, Kearney M, et al. (2010) Analysis of hiv dna molecules in paired peripheral blood and lymph node tissue samples from chronically infected patients. Antiviral Therapy. 15. A41 p.L. JosefssonS. PalmerJ. CasazzaD. AmbrozakM. Kearney2010Analysis of hiv dna molecules in paired peripheral blood and lymph node tissue samples from chronically infected patients.Antiviral Therapy15SupplA41